CTRI/2022/11/047054招募中2 期
A phase 2 randomized, double-blind, parallel-group, placebo and active-controlled, two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active ulcerative colitis
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female, 18 years of age or older with diagnosis of moderate to severe active UC confirmed by endoscopy and histologic evidence at least 6 months prior to screening visit, as defined by a Mayo score
- •2.Patients naïve to biologic therapy (e.g., TNF antagonist) and have a prior OR current UC medication history.
- •3.Before the first administration of study drug, the following conditions must be met
- •a.If receiving conventional immunomodulators (i.e., 6-MP or Azathioprine), must have been taking them for =12 weeks, and on a stable dose for at least 4 weeks.
- •4.A female patient has been sterilized or has been menopausal, or the patient has no pregnancy plan during the trial and voluntarily adopts effective contraceptive measures.
- •5.Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and able to comply with all requirements of the study. Must be able to understand and voluntarily sign an informed consent prior to any study procedures.
排除标准
- •1.Patient with Crohn Disease, indeterminate colitis microscopic colitis, ischemic colitis, or radiation induced colitis, based on medical history, endoscopy, and or histological findings or presence or history of fistula with Crohn Disease or current evidence of fulminant colitis
- •2.History of pancolitis for less than or equal to 8 years or left-sided colitis less than or equal to 15 years.
- •3.Extensive colonic resection or colectomy or
- •imminent risk of colectomy, or prior history of toxic megacolon within 6 months of screening
- •4.History or current evidence of colonic dysplasia or adenomatous colonic polyps.
- •5.Active malignancy or carcinoma in situ within the last 5 years
- •6.Diagnosis of primary sclerosing cholangitis by liver function test.
- •7.Presence or history of active tuberculosis (TB) or latent TB infection,
- •8.Known acute or chronic viral hepatitis B or hepatitis C, or human immunodeficiency virus (HIV).
- •9.Other local or systemic pathological states requiring therapy with corticosteroids within 30 days prior to randomization except inhaled corticosteroids
- •10.Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination.
- •11.Does not agree to use contraception in the event of sexual activity for 130 days after the last dose of study drug if a female of childbearing potential or a male with a partner of childbearing potential.
- •12.Any serious inherited disorder, medical condition, or abnormality of clinical laboratory tests that, in the investigator judgment, precludes the patient safe participation in and completion of the study.
- •13.Evident renal disease or insufficiency, estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
研究者
相似试验
进行中（未招募）
1 期
OBE022 added-on to atosiban in threatened spontaneous preterm labour, Proof of Concept studyoral treatment of threatened spontaneous preterm labour in weeks 24 to 34 of pregnancyMedDRA version: 20.1Level: LLTClassification code 10075863Term: Preterm laborSystem Organ Class: 100000004868EUCTR2017-002579-25-FIObsEva SA130
进行中（未招募）
1 期
OBE022 added-on to atosiban in threatened spontaneous preterm labour, Proof of Concept study.oral treatment of threatened spontaneous preterm labour in weeks 24 to 34 of pregnancyMedDRA version: 20.0 Level: LLT Classification code 10075863 Term: Preterm labor System Organ Class: 100000004868EUCTR2017-002579-25-ESObsEva SA130
未知
2 期
A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the KneeJPRN-jRCT2080220732AstraZeneca
招募中
2 期
A clinical trial to evaluate Anti diabetic potential of ARLPK01CTRI/2014/10/005121ARVIND REMIDIES LTD100
已完成
2 期
SOBERANA CENTROCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusHealthy VolunteersRPCEC00000385Finlay Vaccine Institute (IFV)1,166